Intercept Pharmaceuticals, Inc. Logo
Featured events
Date Event Details Remind Me
Mar 2, 2015
8:30 AM ET
Year-end 2014 Financial Results Conference Call

Participant Dial-In Toll Number:  (315) 625-6894
Participant Dial-In Toll-free Number:  (855) 232-3919
Passcode: not required


Mar 20–21, 2015
AASLD Industry Colloquium: Novel Targets and Therapies in Liver Disease
Location: Hilton Durham Research Triangle Park

http://www.aasld.org/events-professional-development/industry-colloquium

The Industry Colloquium will provide a unique and rare opportunity for interactions between Industry and liver disease experts. Seeking to help identify unmet needs in hepatology, this one and one-half day conference will look toward the future to determine how to address the long-term challenges that hepatologists are likely to face in the coming years.

Course Director

  • Kris V. Kowdley, MD, FACP, FACG, FAASLD

Industry Advisory Panel

  • John G. McHutchison, MD, FAASLD
  • David A. Shapiro, MD
  • Teresa L. Wright, MD, FAASLD
  • Nathaniel A. Brown, MD
  • Juan Carlos Lopez-Talavera, MD, PhD
  • Nikolai V. Naoumov, MD, FAASLD

Mission
To identify unmet needs in liver disease therapy

Learning Objectives

  • Examine unmet needs in the treatment of liver disease
  • Identify new targets and therapies in liver disease
  • Review and facilitate new drug development and approval

Target Audience
Industry R&D and commercial application staff, academic scientists and clinicians

 
Location: 
Hilton Durham Research Triangle Park, North Carolina
 

 

Schedule

Friday, March 20

7:00 am - 8:00 am

Breakfast

Session I: Hepatitis B: Prospects for a Cure (I)
Moderators:  Nathaniel A. Brown, MD and William E. Delaney, MD

8:00 am - 8:20 am

Immunopathogenesis of HBV Infection and Targets
Barbara Rehermann, MD

8:20 am - 8:40 am

Targeting TLRs for Enhancing Durable Responses in HBV
Daniel B. Tumas, MD

8:40 am - 9:00 am

Modulating HBV Core Functions for Durable Treatment Responses
Klaus Klumpp, PhD

9:00 am - 9:20 am

Small Molecule Nucleic Acid Hybrids
RP Kris Iyer, PhD

9:20 am - 9:35 am

Break

Session II: Hepatitis B: Prospects for a Cure (II)
Moderators:  Harry L. Janssen, MD and Nikolai V. Naoumov, MD, FAASLD

9:35 am - 9:55 am

Therapeutic Vaccines
Anuj Gaggar, MD, PhD

9:55 am - 10:25 pm

Global Challenges in Eradication of HBV
Brian McMahon, MD, FAASLD

10:25 am - 10:45 am

Question & Answer/Panel Discussion on Hepatitis B

10:45 am - 11:00 am

Break

Session III: Hepatic Encephalopathy (HE): Diagnosis and Therapy
Moderators:  Bruce F. Scharschmidt, MD, FAASLD and Jasmohan S. Bajaj, MD

11:00 am - 11:20 am

Endpoints in Clinical Trials
Jasmohan S. Bajaj, MD

11:20 am - 11:40 am

Glycerol Phenylbutyrate for Treatment of HE
Bruce Scharschmidt, MD, FAASLD

11:40 am - 12:00 pm

FDA Perspective on Therapies for HE
TBD

12:00 pm - 12:20 pm

Question & Answer/Panel Discussion

12:20 pm - 1:45 pm Lunch and Poster Session

Session IV: Cholestatic Liver Disease: Rational Drug Development
Moderators:  David A. Shapiro, MD and Keith D. Lindor, MD, FAASLD

1:45 pm - 2:05 pm

Surrogate Endpoints in PBC Trials: Are we there yet?
Bettina E. Hansen, PhD, MSc

2:05 pm - 2:25 pm

FGF19 as a Target in Cholestatic Liver Disease
Alex DePaoli, MD

2:25 pm - 2:45 pm

Obeticholic Acid in the Treatment of PBC
David A. Shapiro, MD

2:45 pm - 3:05 pm

ASBT and Treatment of Bile Acid Transport Disorders
Ronald J. Sokol, MD, FAASLD

3:05 pm - 3:25 pm

FDA and Industry Panel Discussion on Cholestatic Disease Endpoints

3:25 pm - 3:40 pm

Break

Session V: Portal Hypertension and Decompensation of Cirrhosis: Bacterial Translocation and Role of the Microbiome
Moderators:  Teresa L. Wright, MD, FAASLD and Bernd Schnabl, MD

3:40 pm - 4:00 pm

Host-Microbial Interaction in Liver Disease
Bernd Schnabl, MD

4:00 pm - 4:20 pm Treatment of Portal Hypertension: Appropriate Endpoints
Don C. Rockey, MD, FAASLD

4:20 pm - 4:40 pm

Altering the Gut Microbiome: Therapeutic Applications

4:40 pm - 5:00 pm

Question & Answer/Endpoints Panel Discussion
Jasmohan S. Bajaj, MD

Saturday, March 21

7:00 am - 8:00 am

Breakfast

Session VI: NASH: Clinical Endpoints and Drug Development (I)
Moderators:  Mary Rinella, MD and David A. Shapiro, MD

8:00 am - 8:20 am

Endpoints in Clinical Trials: Where Are We at Present?
Arun J. Sanyal, MD, FAASLD

8:20 am - 8:40 am

Simtuzamab as a Therapy for NASH
Mani Subramanian, MD, PhD

8:40 am - 9:00 am

Galectin
Peter G. Traber, MD

9:00 am - 9:20 am

Break

Session VII: NASH: Clinical Endpoints and Drug Development (II)
Moderators:  Juan Carlos Lopez-Talavera, MD, PhD and Brent A. Tetri, MD, FAASLD

9:20 am - 9:40 am

Cenicriviroc as Treatment for NASH in Patients with Liver Fibrosis
Eric A. Lefebvre, MD

9:40 am - 10:00 am

Obeticholic Acid for NASH
Brent A. Tetri, MD, FAASLD

10:00 am - 10:30 am

FDA and Industry Panel Discussion on NASH Endpoints

Session VIII: Looking to the Future
Moderators: TBD

10:30 am - 10:55 am

Unmet Needs in Liver Disease Therapy: Prospects for the Future
John G. McHutchison, MD, FAASLD

10:55 am - 11:55 am

Panel Discussion: Advisory Panel Members

11:55 am - 12:15 pm

Conference Summary/Wrap-Up
Kris V. Kowdley, MD, FACP, FACG, FAASLD

 

Email

AASLD Industry Colloquium: Novel Targets and Therapies in Liver Disease

Email Reminder

Please sign up for email alert notification.


Upcoming events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Presentations
Date Title
 
Archived event
Date Event Details
Mar 3, 2015
11:20 AM
Intercept to Present at Cowen Healthcare Conference
Speaker: Mark Pruzanski, M.D., CEO
= add file to Briefcase